Difference between revisions of "Team:Northwestern/Description"
| Line 26: | Line 26: | ||
</div> | </div> | ||
<p><font size="2.6">Antibiotics are among the most frequently administered drugs in human medicine. However, incorrect dosing and failure to complete the prescribed course have contributed to microbes becoming resistant. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited.<font></p> | <p><font size="2.6">Antibiotics are among the most frequently administered drugs in human medicine. However, incorrect dosing and failure to complete the prescribed course have contributed to microbes becoming resistant. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited.<font></p> | ||
| + | </div> | ||
| + | |||
| + | <div> | ||
| + | <h3><center>Our proposed solution</h3></center> | ||
| + | </div> | ||
| + | <p><font size="2.6">Cas9, when bound to guide RNA, results in a versatile gene editing tool that gives rise to a wide range of potential applications. Through non-homologous end joining of the double stranded break, bases are added and subtracted knocking out the gene of interest. Scientists hope to use this system to battle infectious diseases and treat multi-drug resistant microorganisms.Despite the promise behind CRISPR-Cas9, the shift from its use as a research tool to a therapeutic device poses many challenges such as undesirable host immune responses and cleavage in unwanted locations due to low system specificity. Our team is researching the use of Outer Membrane Vesicles (OMVs) as a Cas9 delivery system. We hypothesize that the successful packaging and delivery of Cas9, when combined with a specific guide RNA that defines the genomic target, could be used in a therapeutic setting to combat antibiotic resistance.<font></p> | ||
</body> | </body> | ||
Revision as of 03:18, 13 September 2017
What is the problem we are trying to solve?
Antibiotics are among the most frequently administered drugs in human medicine. However, incorrect dosing and failure to complete the prescribed course have contributed to microbes becoming resistant. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited.
Our proposed solution
Cas9, when bound to guide RNA, results in a versatile gene editing tool that gives rise to a wide range of potential applications. Through non-homologous end joining of the double stranded break, bases are added and subtracted knocking out the gene of interest. Scientists hope to use this system to battle infectious diseases and treat multi-drug resistant microorganisms.Despite the promise behind CRISPR-Cas9, the shift from its use as a research tool to a therapeutic device poses many challenges such as undesirable host immune responses and cleavage in unwanted locations due to low system specificity. Our team is researching the use of Outer Membrane Vesicles (OMVs) as a Cas9 delivery system. We hypothesize that the successful packaging and delivery of Cas9, when combined with a specific guide RNA that defines the genomic target, could be used in a therapeutic setting to combat antibiotic resistance.
